TSX.V: TIGOTCMKTS: NFRGF Frankfurt: 8N61 VANCOUVER, Oct. 19, 2017 /CNW/ - Triumph Gold Corp., (TSX-V: TIG) (OTCMKTS: NFRGF) ("Triumph Gold" or the "Company") is pleased to announce that diamond drilling along the relatively underexplored eastern margin of the Revenue diatreme has been rewarded...Read More
TSX.V: TIGOTCMKTS: NFRGF Frankfurt: 8N61 VANCOUVER, Oct. 19, 2017 /PRNewswire/ - Triumph Gold Corp., (TSX-V: TIG) (OTCMKTS: NFRGF) ("Triumph Gold" or the "Company") is pleased to announce that diamond drilling along the relatively underexplored eastern margin of the Revenue diatreme has been re...Read More
PRESS RELEASE TiGenix to present positive 52-week Phase III results of Cx601 at World Congress of Gastroenterology at ACG 2017 meeting Leuven (BELGIUM) - October 5, 2017, 07:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting...Read More
PRESS RELEASE TiGenix to host Analyst and Investor Event in New York City Leuven (BELGIUM) - October 2, 2017, 07:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived,...Read More
PRESS RELEASE TiGenix to participate and present at key investor and business development meetings Leuven (BELGIUM) - September 28, 2017, 07:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of...Read More
PRESS RELEASERegulated information Key figures for the first half 2017 (consolidated) TiGenix Business and Financial Update for the First Half 2017(Conference call and webcast today at 15:00 CET) Leuven (BELGIUM) - September 19, 2017, 07:00h CET - TiGenix NV (Euronex...Read More
TSX.V: TIGPR # 17-11 OTCMKTS: NFRGF Frankfurt: 8N61 VANCOUVER, Sept. 14, 2017 /CNW/ - Triumph Gold Corp., (TSX-V: TIG) (OTCMKTS: NFRGF) ("Triumph Gold" or the "Company") announces the completion of its 2017 field season.The 2017 exploration campaign began in late May and focused on the Company...Read More
TSX.V: TIGPR # 17-11 OTCMKTS: NFRGF Frankfurt: 8N61 VANCOUVER, Sept. 14, 2017 /PRNewswire/ - Triumph Gold Corp., (TSX-V: TIG) (OTCMKTS: NFRGF) ("Triumph Gold" or the "Company") announces the completion of its 2017 field season.The 2017 exploration campaign began in late May and focused on the...Read More
PRESS RELEASE TiGenix strengthens US operations with senior appointments- Dr. Gregory Gordon appointed as Head of Medical Department (U.S.)- Annette Valles-Sukkar appointed as Associate Director, Clinical ProjectLeuven (BELGIUM) - September 12, 2017, 7:00h CEST - TiGenix NV (Euronext Brussels and...Read More
TSX.V: TIGOTCMKTS: NFRGF Frankfurt: 8N61 VANCOUVER, Sept. 5, 2017 /CNW/ - Triumph Gold Corp., (TSX-V: TIG) (OTCMKTS: NFRGF) ("Triumph Gold" or the "Company") applauds the announcement made on September 2, 2017 by Prime Minister Justin Trudeau and Yukon Premier Sandy Silver committing more than...Read More
PRESS RELEASE TiGenix obtains commercial production license for expanded manufacturing facility- Provides capacity for potential European commercial roll out of investigational stem cell therapy, Cx601 - Expanded facility also secures manufacturing for other pipeline products...Read More
PRESS RELEASE TiGenix opens US headquarters in Cambridge, MA Decision follows NASDAQ IPO in 2016 and the launch of the global phase III trial for Cx601 Operations to be based in Cambridge at heart of Boston area biotech hub High-level team of professionals being recruited to support clinical an...Read More
PRESS RELEASEregulated information Leuven (BELGIUM) - June 12, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies...Read More
PRESS RELEASE TiGenix Launches Global Phase III Trial for Cx601Leuven (BELGIUM) - June 13, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells t...Read More
PRESS RELEASE TiGenix Partners with U.S. and European Patient Advocacy Groups Focused on Crohn's Disease and Ulcerative Colitis- Joins the Crohn's and Colitis Foundation's President's Corporate Circle- Signs Sponsorship Agreement with the European Federation of Crohn's a...Read More
PRESS RELEASE Takeda and TiGenix announce that Swissmedic has accepted for review the file on Cx601 for the treatment of complex perianal fistulas in Crohn's disease patientsPf??ffikon, SZ, June 20, 2017, and Leuven, Belgium, June 20, 2017 - Takeda Pharma AG (TSE: 4502) ("Takeda") and TiGen...Read More
PRESS RELEASE TiGenix to present at the 7th TERMIS-EU Conference in Davos, SwitzerlandLeuven (BELGIUM) - June 23, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or don...Read More